A new vision for addressing treatment gaps for menopausal women.

Learn more about our first-in-class testosterone treatment of clinically significant symptoms associated with hypoandrogenism due to loss of ovarian function in menopausal women.

Our first-in-class testosterone therapy is supported by strong foundational science, championed by physicians and patient advocates who demand better menopause care.

At Eido Bio, we look to close a foundational gap in hormone therapy for 55 million menopausal women.

The Eido Bio Testosterone System will fill the critical gap in comprehensive, foundational hormone care.